Zomedica Corp Stock Price, News & Analysis

Zomedica Corp. (NYSE American: ZOM) announced a strategic update to be presented by CEO Larry Heaton at the H.C. Wainwright Global Investment Conference on September 13, 2022, at 3:00 pm ET. The discussion will cover recent acquisitions and company insights, and the presentation will be available via webcast. Zomedica focuses on veterinary health, providing innovative diagnostics and therapeutic products for companion animals. For more details, visit their website.

Zomedica Corp. (NYSE American: ZOM) announced its PulseVet system has been designated the Official Shock Wave Therapy of the National Cutting Horse Association (NCHA).

This partnership aims to enhance the quality of care for cutting horses, utilizing PulseVet's non-invasive electro-hydraulic shock wave technology to treat various conditions such as tendon injuries and osteoarthritis.

Zomedica's CEO expressed pride in this collaboration, highlighting a shared commitment to animal welfare and performance.

Zomedica Corp. (NYSE American: ZOM) has appointed Dr. Pamela Nichols, a seasoned veterinarian and past president of the American Animal Hospital Association, to its Board of Directors.

Dr. Nichols brings extensive expertise, having founded six veterinary hospitals. Her role emphasizes enhancing Zomedica's strategic initiatives and solutions for veterinary practitioners. CEO Larry Heaton noted her insights will aid in developing innovative technologies for better veterinary care.

This leadership change aims to bolster Zomedica’s mission of improving the quality of care for companion animals.

Zomedica Corp. (NYSE American: ZOM) reported second quarter 2022 financial results with revenue reaching $4.2 million, a significant increase of 51% compared to the same period last year. This surge was largely attributed to the acquisition of PulseVet which contributed $4.2 million in revenue. Gross margin stood at 71%. Despite the revenue growth, Zomedica reported a net loss of $5.3 million, increasing losses by 14%. The company ended the quarter with $186.8 million in cash and equivalents.

Zomedica Corp. (ZOM) announced the acquisition of substantially all assets from Assisi Animal Health LLC, enhancing its portfolio of veterinary health products. Assisi specializes in targeted Pulsed Electromagnetic Field (tPEMF™) devices, which provide drug-free treatments for pain and anxiety in pets. The acquisition is expected to synergize with Zomedica's existing offerings, particularly in therapeutic solutions. Assisi’s products are backed by extensive clinical research, having reportedly helped over 100,000 pets. This strategic move aims to improve pet care while boosting Zomedica's market presence.

Zomedica Corp. (NYSE American: ZOM) announced the expansion of its manufacturing and distribution facility in Roswell, Georgia, on July 7, 2022. The new 12,400 sq. ft. center is part of a larger 61,500 sq. ft. building aimed at increasing production capacity and improving distribution efficiency for its growing product portfolio, including PulseVet, TRUFORMA, Revo2, and VetGuardian. Construction is expected to be completed by August 2022. This expansion underlines Zomedica's commitment to meet rising global demand and enhance operational capabilities.

Zomedica Corp. (NYSE American: ZOM) has successfully completed the acquisition of Revo Squared LLC, integrating its innovative MicroView digital cytology platform. This platform enhances diagnostic accuracy for veterinarians by automating slide preparation, significantly reducing errors. The manufacturing and distribution will shift to Zomedica's expanded facility in Roswell, Georgia, which is expected to optimize production capabilities. The launch of MicroView into the veterinary market is anticipated in 2023.

Zomedica Corp. (NYSE American: ZOM) has been appointed as the Official Shock Wave Therapy Supplier for the United States Equestrian Team Veterinarians through its PulseVet division. PulseVet specializes in electro-hydraulic shock wave technology, aimed at treating various conditions in veterinary patients. The USEF highlighted the partnership's commitment to enhancing horse welfare. The PulseVet system is clinically proven for treating muscle injuries, osteoarthritis, and more. This collaboration emphasizes Zomedica’s role in veterinary health and aligns with its mission to support animal wellness.

Zomedica Corp. (NYSE American: ZOM) announced its participation in the Animal Health, Nutrition & Technology Innovation USA event in Boston from June 21-23, 2022. Greg Blair, Vice President of Business Development, will discuss how Zomedica's innovative products and technologies are assisting veterinarians in adapting to post-COVID challenges. This forum offers insights into emerging trends in animal health and provides networking opportunities with industry executives. Zomedica focuses on creating diagnostic and therapeutic products for companion animals.